November 7, 2014

Advances in melanoma prompt re-evaluation of SLN biopsy
HemOnc Today – Nov. 7
“I continue to believe very strongly in the value of sentinel node biopsy, and our patients continue to choose it as an ideal way to stage their disease and help them make treatment decisions,” Vernon K. Sondak, MD, chair of cutaneous oncology at Moffitt Cancer Center and a HemOnc Today Editorial Board member, said in an interview.

Provectus seeks FDA approval to begin phase 3 trials
Knoxville News Sentinel – Nov. 7
The company's stock rose nearly 9 percent to close at $1.01 after a Moffitt Cancer Center abstract was released earlier in the day that reported positive results when using Provectus' PV-10 drug in combination with other drugs in the treatment of melanoma tumors and in the recurrence of tumors.

Common Myths About Skin Cancer Debunked
U.S. News & World Report – Nov. 6
With skin cancer, there’s this idea that you can scrape, burn or cut it off, and you’re fine, says Vernon Sondak, chair of the department of cutaneous oncology at the Moffitt Cancer Center in Tampa, Florida. “Many times that’s true, but not all the time, and not for all types of skin cancer.”

Saturday fundraiser set for 28-year-old woman battling pancreatic cancer
Tampa Bay Times – Nov. 6
But, due to the rapid advance of the cancer, Blair's less than satisfactory results with conventional treatments and the recommendation by doctors at Moffitt Cancer Center in Tampa, Baylor officials agreed to admit Blair with partial payment up front.

What is optimal use and duration of therapy of bisphosphonates for patients with myeloma related bone disease?
MedPage Today – Nov. 5
Our participants are: Jason Valent, MD, from the department of hematology/oncology at the Cleveland Clinic; Shaji Kumar, MD, of the Mayo Clinic in Rochester, Minn.; Robert Orlowski, MD, of the University of Texas MD Anderson Cancer Center in Houston; and Melissa Alsina, MD, of Moffitt Cancer Center in Tampa, Fla.

M2Gen sets benchmark with $7.3M federal contract
Tampa Bay Business Journal – Nov. 4
Moffitt Cancer Center and M2Gen will play a central role in a new study of a group of blood disorders. The National Institutes of Health’s National Heart, Lung, and Blood Institute awarded Moffitt and its for-profit subsidiary, M2Gen, a contract to serve as the Central Laboratory and Biorepository for The National Myelodysplastic Syndromes Natural History Study.

Maintenance lenalidomide after allogeneic HSCT improved response in high-risk multiple myeloma
Hem/Onc Today – Nov. 3
Melissa Alsina, MD, of the department of blood and marrow transplantation at H. Lee Moffitt Cancer Center and Research Institute, sought to evaluate whether maintenance lenalidomide (Revlimid, Celgene) would reduce the rate of progression after allogeneic hematopoietic stem cell transplantation (HSCT).

Tampa brain cancer patient reacts to Brittany Maynard’s decision to die
WFLA, News Channel 8 – Nov. 3
Radiation and chemo have failed for Michelle Dejong. She’s now in a clinical trial at Moffitt Cancer Center, and hopeful.

Brides Against Breast Cancer nonprofit honored
Sarasota Herald-Tribune – Nov. 3
A portion of that money from 2013 went to develop a cancer support website for patients worldwide with material from the renowned Moffitt Cancer Center.

Annual enrollment period is good time to review Medicare coverage
The Tampa Tribune – Nov. 2
Anyone who plans to rest on the status quo might recall last year’s open enrollment period, when hundreds of Tampa area doctors and the renowned H. Lee Moffitt Cancer Center were dropped from various commercial Medicare policies.

Nivolumab Yields ‘Impressive’ Duration of Response as Late-Line Melanoma Treatment
The ASCO Post – Nov. 1
Nivolumab yielded an “impressive” duration of response when used as second- or third-line treatment for patients with advanced melanoma, according to Jeffrey S. Weber, MD, of the Moffitt Cancer Center in Tampa, Florida, who presented preliminary results of a phase III trial at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid.1

Expert Point of View: Christian Blank, MD, PhD
The ASCO Post – Nov. 1
At the press briefing, Jeffrey S. ­Weber, MD, of the Moffitt Cancer Center in Tampa, Florida, agreed with the new emerging paradigm and suggested the two BRAF/MEK inhibitor combinations are similar in efficacy.

Nivolumab Plus Chemotherapy Shows Similar Efficacy to Nivolumab Monotherapy in NSCLC
OncLive – Nov. 1
Lead author Scott J. Antonia, MD, PhD, a senior researcher at Moffitt Cancer Center in Tampa, Florida, noted that further research is still needed to understand nivolumab’s clinical efficacy when combined with PT-DC.

How will my cancer treatments affect my heart?
The Tampa Tribune – Nov. 1
Dr. Fradley is assistant professor of medicine in the Department of Cardiology at USF Health Morsani College of Medicine. He is also affiliated with Moffitt Cancer Center.

How Elite Institutions Were Affected By A Decade of Constricted Funding
The Cancer Letter – Oct. 31
The eight freestanding cancer centers are: MD Anderson Cancer Center, Dana Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Fred Hutchinson Cancer Center, Fox Chase Cancer Center, Roswell Park Cancer Center, H. Lee Moffitt Cancer Center, and City of Hope Cancer Center.

The Impact of Triple Calamities: Flat Funding, the End of ARRA, & a Loss of Purchasing Power
The Cancer Letter – Oct. 31
Thomas Sellers, director of the H. Lee Moffitt Cancer Center, and Brian Springer, vice president of research administration“These data underscore the reality that cancer funding, adjusted for inflation, is the same today as it was a decade ago. We are losing ground at a time when the opportunities for progress are greater than ever, and this weakens our ability to bring scientific findings to patient care.

City of Hope Launches Blood Cancer Institute
The Cancer Letter – Oct. 31
Martine Extermann received the 2014 Paul Calabresi Award from the International Society of Geriatric Oncology. Extermann is the senior member of the Senior Adult Oncology and Health Outcomes & Behavior Programs at Moffitt Cancer Center.

PV-10 in Metastatic Melanoma: Rapid Responses Led Phase 3
Medscape – Oct. 31
The operant question for researchers, according to Shari A. Pilon-Thomas, PhD, Moffitt Cancer Center Immunology Program, was: “Is it just because you inject the drug and it goes everywhere and then kills tumor cells at other sites? Or is injecting PV-10 inducing a T-cell response, such that T-cells travel throughout the body and kill tumors in their various locations?”

Family raises money for cancer expenses
Plant City Times & Observer – Oct. 31
The transplant will take place at H. Lee Moffitt Cancer Center & Research Institute in Tampa. If it is successful, it will give Wendt at least two more years with her loved ones.

Women Helping Women, Moffitt Merit Society Recognizes The Outstanding Research and Clinical Work of Some Extraordinary Female Scientists
Tampa Bay Metro magazine – October/November 2014
Casual conversation and morning coffee flowed during the January breakfast meeting of the Moffitt Merit Society, but the gathering took a more serious turn when Dr. Dana Rollison spoke about her plans to study possible links between viral infections and skin cancer.


Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.